See more : Bucher Industries AG (0QQN.L) Income Statement Analysis – Financial Results
Complete financial analysis of Gossamer Bio, Inc. (GOSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gossamer Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- James Maritime Holdings, Inc. (JMTM) Income Statement Analysis – Financial Results
- Macarthur Minerals Limited (MMSDF) Income Statement Analysis – Financial Results
- PFA Invest Balance B (PFIBAB.CO) Income Statement Analysis – Financial Results
- Bharat Bhushan Finance & Commodity Brokers Limited (BHARAT.BO) Income Statement Analysis – Financial Results
- Japan Airport Terminal Co., Ltd. (9706.T) Income Statement Analysis – Financial Results
Gossamer Bio, Inc. (GOSS)
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.39M | 4.43M | 5.17M | 4.27M | 3.09M | 297.00K | 0.00 | 0.00 |
| Gross Profit | -4.39M | -4.43M | -5.17M | -4.27M | -3.09M | -297.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 145.30M | 170.92M | 170.27M | 160.85M | 143.40M | 55.28M | 891.00K | 0.00 |
| General & Administrative | 38.46M | 47.61M | 45.78M | 49.73M | 39.14M | 44.05M | 262.00K | 83.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.46M | 47.61M | 45.78M | 49.73M | 39.14M | 44.05M | 262.00K | 83.00K |
| Other Expenses | 0.00 | 1.51M | 799.00K | -174.00K | 5.83M | 316.00K | 0.00 | 0.00 |
| Operating Expenses | 183.76M | 218.53M | 216.05M | 210.58M | 182.54M | 99.33M | 1.15M | 83.00K |
| Cost & Expenses | 183.76M | 218.53M | 216.05M | 210.58M | 182.54M | 99.33M | 1.15M | 83.00K |
| Interest Income | 2.00M | 1.58M | 761.00K | 3.44M | 3.63K | 1.72M | 0.00 | 0.00 |
| Interest Expense | 13.51M | 13.88M | 19.44M | 12.67M | 0.00 | 12.00K | 118.00K | 0.00 |
| Depreciation & Amortization | 1.61M | 4.43M | 5.17M | 4.27M | 3.09M | 297.00K | 1.15M | 83.00K |
| EBITDA | -172.15M | -211.07M | -209.32M | -233.96M | -186.14M | -148.99M | -6.65M | -83.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -183.76M | -218.59M | -216.12M | -233.96M | -186.14M | -148.99M | -6.65M | -83.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.94M | -10.79M | -17.88M | -9.40M | 5.83M | 2.02M | -118.00K | 0.00 |
| Income Before Tax | -179.82M | -229.38M | -234.00M | -243.36M | -180.31M | -146.97M | -6.77M | -83.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 10.85M | 15.07M | 8.22M | 511.00K | 2.04M | -5.38M | -83.00K |
| Net Income | -179.82M | -240.23M | -249.08M | -251.58M | -180.82M | -146.97M | -6.77M | -83.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.18 | -2.84 | -3.33 | -3.67 | -3.30 | -2.43 | -0.27 | 0.00 |
| EPS Diluted | -1.18 | -2.84 | -3.33 | -3.67 | -3.30 | -2.43 | -0.27 | 0.00 |
| Weighted Avg Shares Out | 152.62M | 84.57M | 74.84M | 68.51M | 54.74M | 60.40M | 24.83M | 24.83M |
| Weighted Avg Shares Out (Dil) | 152.62M | 84.57M | 74.84M | 68.51M | 54.74M | 60.40M | 24.83M | 24.83M |
Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021
Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021
Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role
Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q2 2021 Results - Earnings Call Transcript
Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021
Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn's and Colitis Organisation
Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer
Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer
Gossamer Bio Announces Promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs
Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical's Razuprotafib in I-SPY COVID Trial
Source: https://incomestatements.info
Category: Stock Reports